S&P 500   4,267.52 (-0.38%)
DOW   33,665.02 (+0.27%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
S&P 500   4,267.52 (-0.38%)
DOW   33,665.02 (+0.27%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
S&P 500   4,267.52 (-0.38%)
DOW   33,665.02 (+0.27%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
S&P 500   4,267.52 (-0.38%)
DOW   33,665.02 (+0.27%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
NASDAQ:CERT

Certara (CERT) Stock Forecast, Price & News

$18.75
-3.42 (-15.43%)
(As of 06/7/2023 ET)
Compare
Today's Range
$18.60
▼
$22.64
50-Day Range
$19.80
▼
$24.64
52-Week Range
$10.60
▼
$24.96
Volume
3.73 million shs
Average Volume
1.23 million shs
Market Capitalization
$3.00 billion
P/E Ratio
208.33
Dividend Yield
N/A
Price Target
$24.25
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability

Certara MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.63 Rating Score
Upside/​Downside
29.3% Upside
$24.25 Price Target
Short Interest
Bearish
10.45% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.73
Upright™ Environmental Score
News Sentiment
0.57mentions of Certara in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$634,091 Sold Last Quarter
Proj. Earnings Growth
10.81%
From $0.37 to $0.41 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.28 out of 5 stars

Medical Sector

547th out of 982 stocks

Prepackaged Software Industry

122nd out of 207 stocks

See Top Rated MarketRank™ Stocks Here

CERT stock logo

About Certara (NASDAQ:CERT) Stock

Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

Receive CERT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Certara and its competitors with MarketBeat's FREE daily newsletter.

CERT Stock News Headlines

June 7, 2023 | americanbankingnews.com
Certara, Inc. (NASDAQ:CERT) Insider Patrick F. Smith Sells 19,104 Shares of Stock
June 2, 2023 | finance.yahoo.com
Certara to Participate in the Jefferies Global Healthcare Conference
June 7, 2023 | Behind the Markets (Ad)
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
May 22, 2023 | msn.com
Looking Into Certara's Return On Capital Employed
May 17, 2023 | markets.businessinsider.com
Berenberg Bank Reaffirms Their Buy Rating on Certara (CERT)
May 17, 2023 | americanbankingnews.com
Richard M. Traynor Sells 5,000 Shares of Certara, Inc. (NASDAQ:CERT) Stock
May 16, 2023 | finance.yahoo.com
Reasons to Invest in Certara (CERT)
May 14, 2023 | americanbankingnews.com
Analysts Set Certara, Inc. (NASDAQ:CERT) Price Target at $24.25
June 7, 2023 | Behind the Markets (Ad)
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
May 11, 2023 | americanbankingnews.com
Certara (NASDAQ:CERT) Shares Gap Down to $23.42
May 10, 2023 | markets.businessinsider.com
Bank of America Securities Sticks to Their Buy Rating for Certara (CERT)
May 10, 2023 | marketwatch.com
Certara Reports First Quarter 2023 Financial Results
May 9, 2023 | americanbankingnews.com
Certara (NASDAQ:CERT) Issues FY23 Earnings Guidance
May 9, 2023 | finance.yahoo.com
Q1 2023 Certara Inc Earnings Call
May 9, 2023 | americanbankingnews.com
Certara (NASDAQ:CERT) Releases Earnings Results, Meets Expectations
May 9, 2023 | americanbankingnews.com
Head to Head Contrast: Certara (NASDAQ:CERT) and Information Analysis (OTCMKTS:IAIC)
May 7, 2023 | markets.businessinsider.com
Certara earnings preview: what Wall Street is expecting
May 7, 2023 | americanbankingnews.com
Certara (CERT) to Release Earnings on Monday
May 1, 2023 | finance.yahoo.com
Certara, Inc. (CERT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
April 27, 2023 | finance.yahoo.com
Certara Customers Received 90 Percent of US FDA Novel Drug Approvals for 9th Consecutive Year
April 19, 2023 | americanbankingnews.com
Insider Selling: Certara, Inc. (NASDAQ:CERT) SVP Sells 5,000 Shares of Stock
April 19, 2023 | americanbankingnews.com
Brokerages Set Certara, Inc. (NASDAQ:CERT) PT at $24.25
April 16, 2023 | americanbankingnews.com
Analyzing Certara (NASDAQ:CERT) & Porch Group (NASDAQ:PRCH)
April 13, 2023 | msn.com
Stephens & Co. Initiates Coverage of Certara (CERT) with Overweight Recommendation
April 13, 2023 | americanbankingnews.com
Certara (NASDAQ:CERT) Now Covered by Stephens
April 10, 2023 | finance.yahoo.com
Certara to Report First Quarter 2023 Financial Results on May 8th, 2023 and Participate in the BofA Securities 2023 Healthcare Conference
April 5, 2023 | americanbankingnews.com
Certara (NASDAQ:CERT) Rating Lowered to Equal Weight at Barclays
See More Headlines

CERT Price History

CERT Company Calendar

Last Earnings
5/08/2023
Today
6/07/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Prepackaged software
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CERT
CUSIP
N/A
CIK
1827090
Web
www.certara.com
Phone
609-716-7900
Fax
N/A
Employees
1,204
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$24.25
High Stock Price Forecast
$28.00
Low Stock Price Forecast
$19.00
Forecasted Upside/Downside
+29.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.63
Research Coverage
8 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$0.09
Trailing P/E Ratio
208.33
Forward P/E Ratio
50.68
P/E Growth
1.22
Net Income
$14.73 million
Net Margins
4.03%
Pretax Margin
5.07%
Return on Equity
5.53%
Return on Assets
3.84%

Debt

Debt-to-Equity Ratio
0.27
Current Ratio
3.71
Quick Ratio
3.71

Sales & Book Value

Annual Sales
$335.64 million
Price / Sales
8.93
Cash Flow
$0.57 per share
Price / Cash Flow
32.99
Book Value
$6.76 per share
Price / Book
2.77

Miscellaneous

Outstanding Shares
159,830,000
Free Float
155,676,000
Market Cap
$3.00 billion
Optionable
Not Optionable
Beta
1.58

Key Executives

  • Dr. William F. Feehery Ph.D. (Age 52)
    CEO & Director
    Comp: $1.24M
  • Mr. M. Andrew Schemick (Age 49)
    Chief Financial Officer
    Comp: $568.7k
  • Mr. Leif E. Pedersen (Age 59)
    Pres of Software
    Comp: $434.11k
  • Dr. Robert P. Aspbury Ph.D. (Age 51)
    Pres of Simcyp Division
    Comp: $541.23k
  • Mr. Andrew Schemick
    Chief Financial Officer
  • Prof. Amin Rostami PharmD
    Ph.D., FCP, Chief Scientific Officer
  • Mr. Richard M. TraynorMr. Richard M. Traynor (Age 51)
    Sr. VP, Gen. Counsel & Sec.
  • Mr. Ron DiSantis
    Sr. VP of Corp. Devel.
  • Ms. Nicolette D. Sherman (Age 53)
    Chief HR Officer
  • Mr. Jaap Mandema
    Chief Innovation Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













CERT Stock - Frequently Asked Questions

Should I buy or sell Certara stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Certara in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CERT shares.
View CERT analyst ratings or view top-rated stocks.

What is Certara's stock price forecast for 2023?

8 analysts have issued 12 month target prices for Certara's shares. Their CERT share price forecasts range from $19.00 to $28.00. On average, they expect the company's stock price to reach $24.25 in the next twelve months. This suggests a possible upside of 29.3% from the stock's current price.
View analysts price targets for CERT or view top-rated stocks among Wall Street analysts.

How have CERT shares performed in 2023?

Certara's stock was trading at $16.07 at the start of the year. Since then, CERT stock has increased by 16.7% and is now trading at $18.75.
View the best growth stocks for 2023 here.

When is Certara's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our CERT earnings forecast.

How were Certara's earnings last quarter?

Certara, Inc. (NASDAQ:CERT) issued its quarterly earnings results on Monday, May, 8th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.12 by $0.00. The business had revenue of $90.30 million for the quarter, compared to analyst estimates of $91.29 million. Certara had a net margin of 4.03% and a trailing twelve-month return on equity of 5.53%. The firm's revenue was up 10.7% compared to the same quarter last year. During the same period in the prior year, the company earned $0.11 EPS.

What ETFs hold Certara's stock?

ETFs with the largest weight of Certara (NASDAQ:CERT) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH), Janus Henderson US Sustainable Equity ETF (SSPX), BlackRock Future Innovators ETF (BFTR), Convergence Long/Short Equity ETF (CLSE), First Trust Health Care AlphaDEX Fund (FXH), iShares U.S. Healthcare Providers ETF (IHF), SPDR S&P 600 Small Cap Growth ETF (SLYG) and Vanguard S&P Small-Cap 600 Growth ETF (VIOG).

What guidance has Certara issued on next quarter's earnings?

Certara updated its FY 2023 earnings guidance on Monday, May, 8th. The company provided earnings per share guidance of $0.50-$0.55 for the period, compared to the consensus estimate of $0.52. The company issued revenue guidance of $370.00 million-$385.00 million, compared to the consensus revenue estimate of $378.55 million.

When did Certara IPO?

(CERT) raised $500 million in an IPO on Friday, December 11th 2020. The company issued 24,400,000 shares at $19.00-$22.00 per share. Jefferies, Morgan Stanley, BofA Securities, Credit Suisse, Barclays and William Blair acted as the underwriters for the IPO.

What is Certara's stock symbol?

Certara trades on the NASDAQ under the ticker symbol "CERT."

Who are Certara's major shareholders?

Certara's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (9.26%), Baillie Gifford & Co. (5.95%), William Blair Investment Management LLC (4.40%), ArrowMark Colorado Holdings LLC (3.35%), Clearbridge Investments LLC (2.43%) and JPMorgan Chase & Co. (2.31%). Insiders that own company stock include Avatar Parent LP Eqt, Craig R Rayner, James E Cashman III, Jieun W Choe, Justin Edge, Leif E Pedersen, Mason P Slaine, Matthew M Walsh, Michael Andrew Schemick, Patrick F Smith, Richard M Traynor, Robert Aspbury, Stephen M Mclean and William F Feehery.
View institutional ownership trends.

How do I buy shares of Certara?

Shares of CERT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Certara's stock price today?

One share of CERT stock can currently be purchased for approximately $18.75.

How much money does Certara make?

Certara (NASDAQ:CERT) has a market capitalization of $3.00 billion and generates $335.64 million in revenue each year. The company earns $14.73 million in net income (profit) each year or $0.09 on an earnings per share basis.

How many employees does Certara have?

The company employs 1,204 workers across the globe.

How can I contact Certara?

Certara's mailing address is 100 OVERLOOK CENTER SUITE 101, PRINCETON NJ, 08540. The official website for the company is www.certara.com. The company can be reached via phone at 609-716-7900 or via email at ir@certara.com.

This page (NASDAQ:CERT) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -